Morgan Stanley Bio Path Holdings Inc Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$0.36 - $0.75 $252 - $525	700 New	700 $0
Q3 2022 Nov 14, 2022	SELL	$3.18 - $4.43 $28,187 - $39,267	-8,864 Reduced 92.68%	700 $2,000
Q2 2022 Oct 27, 2022	BUY	$2.83 - $4.02 $25,634 - $36,413	9,058 Added 1790.12%	9,564 $37,000
Q2 2022 Aug 15, 2022	BUY	$2.83 - $4.02 $25,634 - $36,413	9,058 Added 1790.12%	9,564 $37,000
Q1 2022 Oct 27, 2022	SELL	$2.99 - $4.17 $27,083 - $37,771	-9,058 Reduced 94.71%	506 $2,000
Q1 2022 May 13, 2022	SELL	$2.99 - $4.17 $56,564 - $78,888	-18,918 Reduced 97.39%	506 $2,000
Q4 2021 Feb 14, 2022	SELL	$3.77 - $5.24 $6,431 - $8,939	-1,706 Reduced 8.07%	19,424 $73,000
Q3 2021 Nov 15, 2021	BUY	$5.13 - $6.78 $108,396 - $143,261	21,130 New	21,130 $108,000

Ticker BPTH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,160,160
Market Cap $6.95M
Description
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.